Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Chronic Obstructive Pulmonary Disease (COPD)
Clinical trial register · China

Chronic Obstructive Pulmonary Disease (COPD) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19212 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:17 UTC
19212
Studies in scope
all four open statuses
11805
Recruiting now
open to new participants
2029
Lead sponsors
across recruiting studies
Top sites
Guangzhou 7 Beijing 7 Chengdu 4 Hangzhou 3 Changsha 3
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou7 Beijing7 Chengdu4 Hangzhou3 Changsha3
All 38 locations
Target enrolment
to

Chronic Obstructive Pulmonary Disease (COPD) trials in China

22 of 19212 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
cfMSC Stem Cell Therapy Targeting COPD
NCT07477600Chronic Obstructive Pulmonary Disease (COPD)
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-30
Not yet open
Cross-Regional Unmanned Aircraft Transport of Donor Lungs
NCT07790822Chronic Obstructive Pulmonary Disease (COPD), Interstitial Lung Disease (ILD), End-stage Lung Disease
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
25
Guangzhou
2026-09-01
Not yet open
High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease
NCT07791979Hypoxemia, Gastric Cancer (Diagnosis), Chronic Obstructive Pulmonary Disease (COPD), Esophageal Cancer
Zhejiang University
Not applicable
90
Hangzhou
2026-08-29
Not yet open
TCM Cohort for Elderly COPD
NCT07780682Chronic Obstructive Pulmonary Disease (COPD)
Henan University of Traditional Chinese Medicine
Observational
2,386
Zhengzhou
2026-08-20
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
630
Guangzhou, Wuhan, Nanchang, Shanghai, Chengdu, Hangzhou, Huzhou, Jiaxing
2026-07-01
Recruiting
Beijing Chao Yang Hospital
Observational
2,800
Beijing
2026-04-01
Recruiting
Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy
NCT07355868Chronic Obstructive Pulmonary Disease (COPD)
Regend Therapeutics
Early Phase 1
12
Yiwu
2026-03-19
Recruiting
IMPACT COPD Cohort (China)
NCT07382986Chronic Obstructive Pulmonary Disease (COPD), Multimorbidities
Beijing Chao Yang Hospital
Observational
10,000
Hebi, Tongliao, Mianyang, Shihezi
2026-02-26
Active, closed
AI-Powered Sound Analysis for COPD Screening
NCT07457073Chronic Obstructive Pulmonary Disease (COPD)
Sir Run Run Shaw Hospital
Observational
3,000
Hangzhou
2026-02-23
Recruiting
Bambusa Therapeutics
Phase 1
68
Hefei, Guangzhou, Jiangmen, Qingyuan, Xinxiang, Yichang, Xuzhou, Nanchang
2025-09-05
Active, closed
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
180
Chengdu
2025-08-13
Recruiting
Immune Status and Disease Control of Inflammatory Airway Diseases
NCT07493629Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Asthma (Diagnosis), Bronchiectasis
First Affiliated Hospital of Ningbo University
Observational
200
Ningbo
2025-08-01
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2
360
Chizhou, Hefei, Lanzhou, Huizhou, Jiangmen, Qingyuan, Zunyi, Langfang
2025-07-15
Recruiting
AstraZeneca
Phase 2
987
Baotou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-06-27
Active, closed
Shared Medical Appointment for COPD Patients (SMA-COPD)
NCT07128745Chronic Obstructive Pulmonary Disease, COPD
Peking University Third Hospital
Not applicable
280
Beijing
2025-06-05
Recruiting
Investigation and Classification of Treatable Traits in Patients With Chronic Airway Diseases
NCT07472738Asthma (Diagnosis), Chronic Obstructive Pulmonary Disease (COPD), Chronic Airway Diseases
Beijing Chao Yang Hospital
Observational
950
Beijing
2025-05-07
Recruiting
Ruijin Hospital
Phase 1/2
20
Qionghai, Shanghai
2025-03-23
Recruiting
AstraZeneca
Phase 3
990
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-03-18
Recruiting
Chronic Airway Disease and Multimorbidity Cohort
NCT06798077Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis
China-Japan Friendship Hospital
Observational
2,000
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Shenyang, Xi'an, Shanghai
2025-02-01
By invitation
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion
NCT06820749Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
309
Beijing
2024-12-10
Recruiting
Nanfang Hospital, Southern Medical University
Observational
2,500
Guangzhou
2024-01-01
Recruiting
Novlead Inc.
Not applicable
16
Nanjing
2023-05-17
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/condition/chronic-obstructive-pulmonary-disease-copd

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,212 studies in total at the last sync on 10 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies listing the condition Chronic Obstructive Pulmonary Disease (COPD).

How many Chronic Obstructive Pulmonary Disease (COPD) trials are recruiting in China?

13 of the 22 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:17 UTC sync. A further 5 have not yet opened recruitment, 3 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chronic Obstructive Pulmonary Disease (COPD)), 22 studies
PhaseStudiesRecruitingShare
Observational8636.4%
Not applicable5122.7%
Phase 24218.2%
Phase 1/2219.1%
Early Phase 1114.5%
Phase 1114.5%
Phase 3114.5%

Most active sponsors

Lead sponsors with the most studies (Chronic Obstructive Pulmonary Disease (COPD))
Lead sponsorStudiesRecruiting
Beijing Chao Yang Hospital33
AstraZeneca22
Haisco Pharmaceutical Group Co., Ltd.20
Bambusa Therapeutics11
China-Japan Friendship Hospital11
First Affiliated Hospital of Ningbo University11
Henan University of Traditional Chinese Medicine10
Mabwell (Shanghai) Bioscience Co., Ltd.11
Nanfang Hospital, Southern Medical University11
Novlead Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.